Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.89 |
| ▸ | HPSE | Q9Y251 | 5/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20456989 | 1.00 | MAPT (0.89) | MAPTHPSE | |
| SCHEMBL21046219 | 1.00 | MAPT (0.89) | MAPTHPSE | |
| SCHEMBL15634985 | 0.99 | MAPT (0.88) | MAPTHPSE | |
| Potassium Ion SCHEMBL28493998 | 0.94 | MAPT (1.00) | MAPTHPSE | |
| Potassium Ion SCHEMBL380009 | 0.94 | MAPT (1.00) | MAPTHPSE | |
| Potassium Ion SCHEMBL29767873 | 0.94 | MAPT (1.00) | MAPTHPSE | |
| Potassium Ion SCHEMBL30190052 | 0.94 | MAPT (1.00) | MAPTHPSE | |
| Water SCHEMBL6357796 | 0.94 | MAPT (0.99) | MAPTHPSE | |
| SCHEMBL19255997 | 0.93 | MAPT (0.78) | MAPTHPSE | |
| SCHEMBL25014383 | 0.88 | MAPT (0.78) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10161929-B2 | Theranostics platform and methods of use | Sanford Burnham Prebys Medical Discovery (US) | 2018-12-25 | — | — | US | disclosed |
| US-20180338899-A1 | INHIBITORS FOR METHYLATION-RELATED ENZYMES HAT1 AND KAT8 | MIURA NORIMASA (JP) | 2018-11-29 | — | — | US | disclosed |
| EP-3369434-A1 | INHIBITORS FOR METHYLATION-RELATED ENZYMES HAT1 AND KAT8 | MIURA, Norimasa (JP) | 2018-09-05 | — | — | EP | disclosed |
| US-10004701-B2 | Methods and compositions for treating infection | UNIVERSITY OF ROCHESTER (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170065540-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | UNIVERSITY OF ROCHESTER (US) | 2017-03-09 | — | — | US | disclosed |
| US-9393221-B2 | Methods and compounds for reducing intracellular lipid storage | THE GENERAL HOSPITAL CORPORATION (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150238473-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-27 | — | — | US | disclosed |
| EP-2767275-A1 | Nortriptyline, haloperidol or prochlorperazine edisylate for use in the treatment of tuberculosis as well as two screening methods | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-08-20 | — | — | EP | disclosed |
| WO-2013123403-A1 | THERANOSTICS PLATFORM AND METHODS OF USE | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2013-08-22 | — | — | WO | disclosed |
| US-20130023488-A1 | METHODS AND COMPOUNDS FOR REDUCING INTRACELLULAR LIPID STORAGE | THE GENERAL HOSPITAL CORPORATION (US) | 2013-01-24 | — | — | US | disclosed |
| US-20100305326-A1 | Chemical Fragment Screening and Assembly Utilizing Common Chemistry for NMR Probe Introduction and Fragment Linkage | MARQUETTE UNIVERSITY (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100304998-A1 | Chemical Proteomic Assay for Optimizing Drug Binding to Target Proteins | MARQUETTE UNIVERSITY (US) | 2010-12-02 | — | — | US | disclosed |
| WO-1999006588-A1 | A CELL-FREE SYSTEM OF MITOCHONDRIA-DEPENDENT APOPTOSIS, AND METHODS OF USE THEREOF | THE BURNHAM INSTITUTE (US) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238473-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | MMP8, IFNG, MPO | MAPT 4152/4885HPSE 392/4885 |
| US-20100305326-A1 | Chemical Fragment Screening and Assembly Utilizing Common Chemistry for NMR Probe Introduction and Fragment Linkage | CYFIP2, RPS27A, FRS2 | MAPT 2128/4885HPSE 2156/4885 |
| US-20170065540-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | MMP8, IFNG, MPO | MAPT 4152/4885HPSE 392/4885 |
| US-10004701-B2 | Methods and compositions for treating infection | MMP8, IFNG, MPO | MAPT 4152/4885HPSE 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.